BioCentury | Oct 24, 2016
Product Development

A new BEAT for AML

...tyrosine kinase (SYK) inhibitor Undisclosed Ph II Candidates from ASH presentations Array BioPharma Inc. (NASDAQ:ARRY) ARRY-382...
BioCentury | Jul 23, 2015
Distillery Therapeutics

Therapeutics: Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115)

...targeting CSF1R, in Phase II to treat solid tumors and inflammation. Array BioPharma Inc. has ARRY-382...
BioCentury | Oct 31, 2013
Distillery Therapeutics

Indication: Cancer

...status of the compound is undisclosed. Array BioPharma Inc. has the small molecule CSF1R inhibitor ARRY-382...
BioCentury | Dec 6, 2010
Company News

Array BioPharma, Celgene deal

...programs for cancer and inflammation. The payment was triggered after FDA approved Array's IND for ARRY-382...
...to treat cancer next quarter. If Celgene exercises its option to obtain exclusive rights to ARRY-382...
Items per page:
1 - 4 of 4